Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Accelerating hospital adoption of Mako robotics drives outsized pull-through in orthopaedic implants, while MedSurg cross-selling increases revenue per hospital, expanding operating margins beyond 22%.
Multiple Contraction to Peer Median: SYK's PEG of 2.51 compresses to the med-tech peer median of 1.56 as Mako-driven growth normalizes.
Stryker is a high-quality mature compounder with a durable moat derived from high switching costs, scale economies, and deep hospital relationships across MedSurg and Orthopaedics. The continued adoption of Mako robotics provides a strong catalyst for market share gains and implant pull-through.
Stryker is a high-quality mature compounder with a durable moat derived from high switching costs, scale economies, and deep hospital relationships across MedSurg and Orthopaedics. The continued adoption of Mako robotics provides a strong catalyst for market share gains and implant pull-through.
High switching costs in hospital ecosystems
Scale economies in MedSurg and Orthopaedics
Accelerating hospital capital expenditures and aging demographics driving elective procedure volumes.
Hold. The current valuation fully prices in the high-quality compounding nature and Mako robotics growth.
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
A sustained hospital CapEx freeze slows Mako placements, while aggressive GPO negotiations compress implant ASPs, pushing operating margins below 19% and compressing the multiple.
High switching costs in hospital ecosystems
Scale economies in MedSurg and Orthopaedics
Mako robotics ecosystem lock-in
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $4.1B after capex $753.5M, with terminal value at 66.5% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If Mako placements beat estimates, watch for margin expansion. If margins miss 20.5%, expect multiple compression.
If Mako placements beat estimates, watch for margin expansion. If margins miss 20.5%, expect multiple compression.
If Mako placements beat estimates, watch for margin expansion. If margins miss 20.5%, expect multiple compression.
If Mako placements beat estimates, watch for margin expansion. If margins miss 20.5%, expect .
Steady reinvestment in robotic capabilities and tuck-in acquisitions.
Accelerating hospital capital expenditures and aging demographics driving elective procedure volumes.
Constrained hospital budgets and delayed elective procedures due to macro pressure or staffing shortages.
Steady reinvestment in robotic capabilities and tuck-in acquisitions.
Market weight due to current fair value alignment and high multiple risk.
Trim if the forward multiple expands beyond historical 25x bounds without concurrent ROIC acceleration.
Hold.
Stryker is a phenomenal business priced for perfection. The 20x terminal multiple is supported by maturity but leaves little room for error compared to cheaper peers.
Hold.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Macroeconomic pressures constrain hospital capital expenditure budgets, slowing down the adoption of robotics and MedSurg equipment. Increased competition in the orthopaedics space leads to pricing pressure and margin contraction.
SYK's PEG of 2.51 compresses to the med-tech peer median of 1.56 as Mako-driven growth normalizes.
Hospital GPOs successfully leverage increased competition to drive down orthopaedic implant pricing.
Macroeconomic pressures severely constrain hospital capital expenditure budgets, halting Mako placements.
The five developments that would weaken our investment case.
Operating margin erosion indicates that elevated hospital sales costs and pricing pressure are outweighing robotics operational leverage, undermining earnings compounding assumptions.
Current:20.1% for the period ended 2025-12-31
Alert if< 19.0% over two consecutive fiscal quarters
Top-line deceleration demonstrates that hospital capital expenditure freezes are curbing robotic system installations, directly impeding high-margin recurring consumables and surgical implant pull-through.
Current:11.2% for the period ended 2025-12-31
Alert if< 6.0% over any trailing twelve-month period
Gross margin contraction reflects successful pricing concessions demanded by group purchasing organizations, neutralizing technological product differentiation and crimping gross profit expansion.
Current:64.0% for the period ended 2025-12-31
Alert if< 61.0% over any two consecutive fiscal quarters
Declining capital efficiency shows that capital allocation across acquired medical device portfolios is diluting corporate returns, removing justification for valuation multiples above industry medians.
Current:10.6% as of 2026-05-12
Alert if< 8.5% over any trailing twelve-month period
Weakened operating cash conversion indicates lengthening hospital payment cycles and bloated channel inventories, signaling slowing sales velocity across core equipment lines.
Current:1.554 as of 2026-05-12
Alert if< 1.000 over any full fiscal year
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Accelerating hospital adoption of Mako robotics drives outsized pull-through in orthopaedic implants, while MedSurg cross-selling increases revenue per hospital, expanding operating margins beyond 22%.
SYK maintains its premium multiple through consistent execution, holding 20.5% operating margins and mid-to-high single-digit revenue growth supported by steady Mako placements.
Warning level: < 19.0% over two consecutive fiscal quarters. Operating margin erosion indicates that elevated hospital sales costs and pricing pressure are outweighing robotics operational leverage, undermining earnings compounding assumptions.
Warning level: < 6.0% over any trailing twelve-month period. Top-line deceleration demonstrates that hospital capital expenditure freezes are curbing robotic system installations, directly impeding high-margin recurring consumables and surgical implant pull-through.
Warning level: < 61.0% over any two consecutive fiscal quarters. Gross margin contraction reflects successful pricing concessions demanded by group purchasing organizations, neutralizing technological product differentiation and crimping gross profit expansion.
Warning level: < 8.5% over any trailing twelve-month period. Declining capital efficiency shows that capital allocation across acquired medical device portfolios is diluting corporate returns, removing justification for valuation multiples above industry medians.
Warning level: < 1.000 over any full fiscal year. Weakened operating cash conversion indicates lengthening hospital payment cycles and bloated channel inventories, signaling slowing sales velocity across core equipment lines.
| $20.50B |
| $22.60B |
| $25.12B |
| +10.8% |
| Gross profit | $11.58B | $13.06B | $14.44B | $16.07B | +11.5% |
| Operating income | $3.11B | $4.04B | $3.90B | $5.12B | +18.1% |
| Net income | $2.36B | $3.17B | $2.99B | $3.25B | +11.2% |
| EPS (diluted) | $6.17 | $8.25 | $7.76 | $8.40 | +10.8% |
| EBITDA | $4.11B | $5.06B | $4.95B | $6.31B | +15.4% |
| R&D | $1.45B | $1.39B | $1.47B | $1.62B | +3.7% |
| SG&A | $6.39B | $7.11B | $7.69B | $8.65B | +10.6% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 25,116,000,000 |
|---|---|
| Cost of revenue | 9,051,000,000 |
| Gross profit | 16,065,000,000 |
| Operating expenses | 11,006,000,000 |
| Operating income | 5,059,000,000 |
| Non-operating items and tax | -1,813,000,000 |
| Net income | 3,246,000,000 |
| Total assets | 47,844,000,000 |
|---|---|
| Cash | 4,011,000,000 |
| Current assets | 14,755,000,000 |
| Total liabilities | 25,424,000,000 |
| Current liabilities | 7,794,000,000 |
| Shareholders’ equity | 22,420,000,000 |
Point-in-time financial data used in the 2026-05-12 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | — | — | — | — | — | — | — | — | 0 | — | — | — | — | — | — | — | — | — | — | — | — |
| 2022-12-31 | 18.4B | 4.1B | 2.4B | 2.6B | 2B | 588M | 998M | 168M | — | 1.1B | 472M | — | — | — | — | 1.8B | 13B | 16.9% | — | — | — |
| 2023-12-31 | 20.5B | 5.1B | 3.2B | 3.7B | 3.1B | 575M | 1B | 205M | — | 1.1B | -277M | — | — | — | — | 3B | 13B | 19.1% | — | 7.7% | — |
| 2024-12-31 | 22.6B | 5B | 3B | 4.2B | 3.5B | 755M | 1.1B | 229M | — | 1.2B | 940M | — | — | — | — | 3.7B | 13.6B | 20.7% | — | 8.7% | — |
| 2025-12-31 | 25.1B | 6.3B | 3.2B | 5B | 4.3B | 761M | 1.2B | 243M | — | 1.3B | 1.6B | — | — | — | — | 4B | 15.9B | 20.1% | — | 7.8% | — |
SYK trades at 17.6x forward earnings against a peer median of 13.6x; EV/EBITDA of 17.3x against a peer median of 14.6x; 6 peers.
| Wait for a pullback closer to $250 or structural margin expansion evidence. |
| Medtronic plc |
| 12.3x |
| 2.7x |
| 12.2x |
| 9.4% |
| 20.0% |
| BSX | Boston Scientific Corporation | 14.2x | 3.8x | 16.2x | 14.7% | 20.6% |
| EW | Edwards Lifesciences Corporation | 22.9x | 7.0x | 22.6x | 10.5% | 31.2% |
| GEHC | GE HealthCare Technologies Inc. | 11.5x | 1.3x | 10.4x | 19.5% | 11.1% |
